DEA Judge Blocks Researcher’s Motion In Cannabis Rescheduling Case,
A DEA administrative law judge has denied MedPharm’s motion to participate in the December 2 marijuana rescheduling hearing, deferring to DEA Administrator Anne Milgram’s authority.
MedPharm, a DEA-registered research firm, criticized the exclusion of marijuana researchers and the inclusion of prohibitionist organizations, calling the process biased.
MedPharm’s Motion And Criticism
MedPharm filed a motion to intervene after being excluded from the witness list, arguing the fact that no DEA-licensed marijuana researchers were included.
“The deck appears to be stacked against those in favor” of rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), MedPharm noted.
It also alleged that the witness list, which included the anti-cannabis prohibitionist group …